Genmab (GNMSF)
(Delayed Data from OTC)
$287.80 USD
+6.67 (2.37%)
Updated May 14, 2024 03:28 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GNMSF 287.80 +6.67(2.37%)
Will GNMSF be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GNMSF based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for GNMSF
Genmab A/S 2024 Q1 - Results - Earnings Call Presentation
Genmab A/S (GMAB) Q1 2024 Earnings Call Transcript
Genmab to purchase US-based biotech company ProfoundBio for $1.8 billion in all-cash deal
Genmab A/S (GMAB) Q4 2023 Earnings Call Transcript